期刊文献+

拉米夫定治疗失代偿期乙型肝炎后肝硬化20例疗效分析 被引量:2

下载PDF
导出
摘要 业已证实,乙型肝炎(以下简称乙肝)是我国引起肝硬化的主要原因,而乙肝病毒(HBV)则在其病情进展中起着很重要的作用。肝硬化进入失代偿期后肝功能损害严重,且并发症较多,病情易反复,预后较差。而近年来多项研究结果已证实,拉米夫定(LAM)具有较强的抗HBV作用;近年来笔者对失代偿期乙肝后肝硬患者予LAM进行抗病毒治疗,取得了较为满意的疗效,现将结果报道如下。
出处 《浙江医学》 CAS 2010年第3期429-430,共2页 Zhejiang Medical Journal
基金 金华市科技局科研项目(2007-3-083):磐安县科技局重点科研项目(2007-17)
  • 相关文献

参考文献6

  • 1慢性乙型肝炎防治指南[J].中华传染病杂志,2005,23(6):421-431. 被引量:824
  • 2Leung N.Liver disease-significant impovement with lamivudine[J].J Med Vir,2000,61:380-385. 被引量:1
  • 3Chen C J,Yang H I,Su J,et al.Occurrence of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA,2006,295:6 5-73. 被引量:1
  • 4Sponseller C A,Baconn B R,Bisceglie A M.Clinical improvement in patients with decompensated liver disease caused hepatitis B after treatment with lamivudine[J].Liver Transplogy,2000,6:715-720. 被引量:1
  • 5Kweon Y O,Goodman Z D,Dienstag J L,et al.Decreasing fibrogenesis:an immunohistochemincal study of paired liver biopsies following lamivudine therapy for chronic hepatitis B[J].J Heptol,2001,35:749-755. 被引量:1
  • 6王宇明,张南,邓国宏.慢性乙型肝炎失代偿性肝硬化的抗病毒治疗[J].中华临床感染病杂志,2008,1(4). 被引量:3

二级参考文献35

共引文献825

同被引文献29

  • 1Perrillo RP;Wright T;Rakela J.A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B[J],2001(02). 被引量:1
  • 2Dienstag JL;Schiff ER;Wright TL.Lamivudine as initial treatment for chronic hepatitis B in the United States[J],1999(17). 被引量:1
  • 3Peters M;Schiff E;Benhamou Y.Adefovir dipivoxil demonstrates antiviral efficacy and clinical benefit in the treatment of lamivudine resistant chronic HBV:an analysis of four clinical trials,2002. 被引量:1
  • 4Leung NW;Lai CL;Chang Tr.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy[J],2001(06). 被引量:1
  • 5Perz JF;Armstrong GL;Farrington LA.The contributions of hepatitis B vires and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J],2006(04). 被引量:1
  • 6Berenguer M;Prieto M;Ray6n M.Famciciovir treatment in transplant recipients with HBV-related liver disease:disappointing results[J],2001(02). 被引量:1
  • 7Lai CL;Yuen MF;Hui CK.Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B:results of 24 weeks of therapy[J],2002(03). 被引量:1
  • 8Hoofnagle JH;Di Bisceglie AM;Waggoner JG.Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B,1993(04). 被引量:2
  • 9Lin SM;Sheen IS;Chien RN.Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection[J],1999(03). 被引量:1
  • 10Lai L;Hui CK;Lcong N.Pegylated interferon alpha-2a(40 kDa) in the treatment of chronic hepatitis B,2006(03). 被引量:1

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部